X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PIRAMAL ENTERPRISES DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 31.9 9.1 350.0% View Chart
P/BV x 5.2 3.0 171.4% View Chart
Dividend Yield % 1.0 0.8 118.7%  

Financials

 DIVIS LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PIRAMAL ENTERPRISES
Mar-17
DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2222,095 58.3%   
Low Rs7841,025 76.5%   
Sales per share (Unadj.) Rs153.1492.8 31.1%  
Earnings per share (Unadj.) Rs39.972.6 55.1%  
Cash flow per share (Unadj.) Rs44.694.7 47.1%  
Dividends per share (Unadj.) Rs10.0021.00 47.6%  
Dividend yield (eoy) %1.01.3 74.1%  
Book value per share (Unadj.) Rs201.8862.5 23.4%  
Shares outstanding (eoy) m265.47172.56 153.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.2 207.0%   
Avg P/E ratio x25.121.5 116.8%  
P/CF ratio (eoy) x22.516.5 136.5%  
Price / Book Value ratio x5.01.8 274.8%  
Dividend payout %25.028.9 86.5%   
Avg Mkt Cap Rs m266,266269,194 98.9%   
No. of employees `0009.74.0 242.6%   
Total wages/salary Rs m4,68717,939 26.1%   
Avg. sales/employee Rs Th4,175.021,190.3 19.7%   
Avg. wages/employee Rs Th481.54,470.1 10.8%   
Avg. net profit/employee Rs Th1,089.33,120.0 34.9%   
INCOME DATA
Net Sales Rs m40,64385,037 47.8%  
Other income Rs m7492,338 32.0%   
Total revenues Rs m41,39287,374 47.4%   
Gross profit Rs m14,46034,991 41.3%  
Depreciation Rs m1,2333,817 32.3%   
Interest Rs m2320,310 0.1%   
Profit before tax Rs m13,95313,202 105.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m3,3492,281 146.8%   
Profit after tax Rs m10,60412,520 84.7%  
Gross profit margin %35.641.1 86.5%  
Effective tax rate %24.017.3 138.9%   
Net profit margin %26.114.7 177.2%  
BALANCE SHEET DATA
Current assets Rs m40,10587,590 45.8%   
Current liabilities Rs m6,595185,578 3.6%   
Net working cap to sales %82.5-115.2 -71.6%  
Current ratio x6.10.5 1,288.5%  
Inventory Days Days11931 381.9%  
Debtors Days Days8148 169.7%  
Net fixed assets Rs m19,995108,523 18.4%   
Share capital Rs m531345 153.8%   
"Free" reserves Rs m53,043148,481 35.7%   
Net worth Rs m53,574148,826 36.0%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m61,585482,394 12.8%  
Interest coverage x618.41.7 37,478.4%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.70.2 374.4%   
Return on assets %17.36.8 253.5%  
Return on equity %19.88.4 235.3%  
Return on capital %26.112.0 218.3%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38415,001 235.9%   
Fx outflow Rs m10,3995,150 201.9%   
Net fx Rs m24,9859,851 253.6%   
CASH FLOW
From Operations Rs m11,493-100,393 -11.4%  
From Investments Rs m-11,372-24,202 47.0%  
From Financial Activity Rs m-93135,705 -0.1%  
Net Cashflow Rs m2811,110 0.3%  

Share Holding

Indian Promoters % 52.0 52.9 98.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.0 295.0%  
FIIs % 19.0 26.6 71.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 16.5 104.2%  
Shareholders   31,796 93,274 34.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 25, 2018 11:35 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS